Fluoropyrimidines have shown efficacy against a variety of cancers and have evolved into a range of different uses and formulations. These drugs have been tested extensively as monotherapies and as part of numerous different chemotherapy combinations. The efficacy and safety profile of bolus intravenous (IV) 5-fluorouracil (5-FU) has been improved by continuous IV administration. The availability of the first 5-FU oral form in Europe, capecitabine, has added a clear value in terms of convenience for patients, while forcing physicians and nurses to learn how to manage the toxicity profile of this compound. S-1 is a new oral formulation combining a 5-FU prodrug (tegafur) and two targeted modulators of its metabolism (gimeracil and oteracil) preserving the efficacy and improving the safety of the prodrug. S-1 has become the backbone treatment for advanced gastric cancer in Japan since its introduction in 1999. Extensive experience from clinical trials, post-marketing studies and patient registries of over 4,000 patients in Japan show that S-1 has improved measures of survival in advanced gastric cancer and has an acceptable safety profile. S-1 has recently been approved for advanced gastric cancer treatment Following the recent approval of S-1 for use in Western populations after more than 10 years of extensive experience in Japan, the history of the fluoropyrimidines in advanced gastric cancer will be considered, and evidence supporting the use of S-1 from early phases to more recent clinical studies will be reviewed.
The fluoropyrimidine drug 5-fluorouracil (5-FU) was originally Following the recent approval of S-1 for use in Western populations after more than 10 years of extensive experience in Japan, the history of the fluoropyrimidines in advanced gastric cancer will be considered, and evidence supporting the use of S-1 from early phases to more recent clinical studies will be reviewed. In terms of reducing fluoro-beta-alanine levels by blocking the catabolism of 5-FU, all clinically available fluoropyrimidines can be distinguished into two classes: those that inhibit degradation, known as DPD inhibitory fluoropyrimidines (DIF), including tegafur-uracil, eniluracil and S-1, and those that do not contain a catabolism inhibitor such as IV 5-FU and capecitabine. Essentially, the DIF type of blocking agents substantially reduces fluoro-beta-alanine production and would be expected to reduce toxicity such as the incidence of HFS.
Patients receiving drugs of the DIF category have very low levels of HFS all grades, whereas patients receiving capecitabine show a high incidence of HFS, as do recipients of continuous infusion FU with bolus. When DIF compounds, including S-1, are employed, the incidence of grade 3-4 HFS is reduced to almost zero, as opposed to a 10 % level of severe toxicity with non-DIF compounds. In cancer treatments, theory and preclinical data rarely correspond exactly; but these findings are an example of a correspondence between a postulated mechanism and actual clinical data.
Animal studies involving treatment with a fluoropyrimidine without interference with the RNA-directed pathway, including the activation modulator, resulted in a serious degradation of the intestinal villi and crypts. When oteracil was added however, the anti-RNA effect was blocked and the intestinal villi were protected, as well as the crypts.
In a study of 3,800 patients with gastric cancer who were receiving at least fluoropyrimidine plus oteracil treatment and listed in Japanese registry, the incidence of Grade 3-4 diarrhoea was only 2 %. 8 This
The Need for a New Fluoropyrimidine in Advanced Gastric Cancer Treatment showed non-inferiority of the S-1 plus cisplatin regimen. 3 From these results it may be concluded that in efficacy terms, capecitabine is roughly equal to IV 5-FU and that S-1 is equal to IV 5-FU. However, it cannot be concluded that S-1 is completely equal to capecitabine. In terms of safety, the FLAGS study found that S-1 had a significantly improved safety profile compared to IV 5-FU and cisplatin. 3 To obtain meaningful safety comparisons between different cancer treatments, a comparable criterion must be defined. HFS is one of the most frequent adverse events necessitating a dose reduction or treatment interruption for capecitabine. The frequency of this parameter and the ability to monitor it in patients has made it a criterion of choice. Moreover, capecitabine-based regimens have shown an overall incidence of HFS of approximately 50 % and a severe incidence of approximately 10 %, whereas, in the FLAGS study, S-1 showed an incidence of less than 6 % with severe grade incidence of less than 1 % (see Table 1 ).
In addition to the randomised Phase III studies, a Phase II study conducted in South Korea (n=129) compared S-1 + oxaliplatin (SOX) with capecitabine + oxaliplatin (CAPOX) in advanced gastric cancer patients. 6 Both the SOX and CAPOX regimens were equally active and well tolerated. A 25 % incidence of all grades of HFS was observed for CAPOX versus only 3.1 % for SOX. In addition, a 1.6 % incidence of grade 3/4 HFS was seen in the CAPOX group versus 0 % in the SOX group. Grade 3/4 neuropathy, nausea, vomiting and asthenia were also less frequent with SOX.
The occurrence of a relevant adverse event, HFS, in indirect Phase III and direct Phase II comparisons of the different oral 5-FUs raises the following question for oncologists: "What will be your choice in daily practice for the treatment of your patients with advanced gastric cancer?"
S-1 (Teysuno ® ) -10 Years of Savoir-faire in Asia
The mortality rate due to gastric cancer in Japan has decreased continuously since the 1960s. Gastric cancer, however, remains the second highest cause of cancer-related death, ranking second for males and third for females in Japan. 9 The five-year survival rates for gastric cancer between 1990 and 1994 at the National Cancer
Center Hospital in Japan were not satisfactory at any disease stage, particularly for stage IV for which the rate is less than 10 %. were neutropenia and diarrhoea, with only a 2 % incidence rate.
Moreover, the median OS were 250 and 207 days, whereas the one year OS rates were 37 and 36 %, respectively.
In the Japanese Nationwide Post-Marketing Survey of S-1, involving 3,808 Japanese patients, the toxicity profile of S-1 was shown to be similar to that reported in the late Phase II studies. Diarrhoea of grade ≥3 was only 2 %, but the incidence of neutropenia was 6 %. The toxicity of S-1, especially haematological toxicity, was related to creatinine
clearance. This was not surprising given that CDHP, which is a DPD inhibitor, is excreted from the kidney. In patients with renal failure, the incidence of haematological toxicities was higher: 40 % (8/20) for a standard initial dose versus 23.5 % (4/17) for a reduced initial dose (for patients with creatinine clearance values <30 mL/min). 8 Therefore, when administering S-1, renal function must be checked and dose adjustments must be made according to age and gender.
Conference Proceedings Compared with other Japanese Phase II clinical trials of other fluoropyrimidines or cytotoxic agents, S-1 monotherapy was extremely high (see Table 2 ). In Japan, S-1 plus cisplatin is currently the standard first-line treatment and 70 to 80 % of patients will eventually receive second-line treatment with irinotecan, docetaxel or paclitaxel monotherapy. More than 50 % of these patients will receive chemotherapy that includes paclitaxel.
Another promising gastric cancer treatment regimen is S-1 plus oxaliplatin (SOX). In a Phase II study investigating this combination, Oxaliplatin (100 mg/m 2 , D1) plus S-1 (80-120 mg/m 2 , D1-14, q3w) were administrated in the patients. 28 The response rate was 59 %. The most commonly observed grade 3 or 4 toxicities were neutropenia in 22 % and thrombocytopenia in 13 % of patients. The median OS was 16.5 months. This trial led to an ongoing Phase III trial (n=680) in Japan that is to evaluate non-inferiority of PFS and OS comparing SOX versus S-1 plus cisplatin.
An alternative approach to gastric cancer treatment was evaluated in a Phase I/II trial in which patients received a triplet of docetaxel, cisplatin and S-1 (DCS). Docetaxel (40 mg/m 2 ) and cisplatin (60 mg/m 2 )
were given on day 1 of 28-day cycle; S-1 (40 mg/m 2 ) was given twice daily on days 1-14. 29 The most commonly observed grade 3/4 toxicity was neutropenia in 70 % of patients. The median PFS was 8.7 months and the median OS was 18.5 months. This DCS regimen showed marked efficacy against intestinal and diffuse types of gastric cancer.
In this study, down-staging of gastric cancer was achieved in nine (19 %) of 48 patients who responded to DCS.
The DCS is also being compared with a S-1 and cisplatin and combination in another ongoing Phase III trial in patients with unresectable, recurrent or advanced gastric cancer in Japan (JCOG 1013) (see Figure 2) . The aim of this study is to evaluate superiority of OS (n=740).
For HER2-positive gastric cancer patients, there are currently three
Phase II clinical trials with S-1 in progress in Japan and Southeast Asia
The Need for a New Fluoropyrimidine in Advanced Gastric Cancer Treatment In clinical use, combination regimens that include S-1 are likely to extend the lives of many patients with advanced gastric cancer.
Established Benefits of S-1 Confirmed in Western Populations
Asian patients, particularly the Japanese, have a markedly different metabolism of anti-cancer drugs compared with Western populations.
This phenomenon has been observed with drugs such as 5-FU for which the doses used in Asian patients are much higher than are normally used in Caucasians.
The combination of S-1 and cisplatin is highly active in Japanese patients with advanced gastric cancer. Following the discovery of regional dose variations of one of the S-1 components, it was necessary early in drug development to define the optimal dosing of both S-1 and cisplatin in combination for use in a Caucasian patient population. This necessitated a Phase I pharmacokinetic study in which a combination of S-1 and cisplatin were used to treat advanced gastric carcinoma. 30 In the Japanese population, given an S-1 dose of 32 to 40 mg/m 2 , the exposure, as expressed as the AUC, is around 700 ng x h/mL.
In the Caucasian population, to reach a similar AUC with an acceptable tolerability, it is necessary to decrease to a dose of 25 mg/m 2 in combination with cisplatin and it is necessary to decrease to 30 mg/m 2 in monotherapy. 30b The design of this Phase I trial allowed various levels of dose escalation, and concluded that the recommended doses were 25 mg/m 2 for S-1 and 75 mg/m 2 for cisplatin. At these doses, the incidence of grade 3/4 toxicities was very low although this was a small Phase I study; 6 patients receiving These consisted of fatigue/asthenia (grade 3/4) in 24 %, diarrhoea (grade 3 /4) in 13 %, a low incidence of stomatitis, and a low incidence of febrile neutropenia. This is considered to be an acceptable toxicity profile.
The findings of this study led to the FLAGS study, a multi-centre, The cancers were primarily of the stomach, a few subjects had gastro-oesophageal junction disease, and the diffuse histological type was slightly more frequently than the non-diffuse type. Metastatic disease was present in almost all the patients with two-thirds of the patients having more than two metastatic sites and most were measurable. Very few patients had received prior adjuvant chemotherapy and approximately one-third had prior stomach resection.
There was no major difference in treatment compliance between the two arms and the median number of cycles per patient was four, ranging from one to 28 or one to 24. The dose intensities of S-1 and
Conference Proceedings 5-FU were similar (92 and 95 %, respectively). The duration of treatment was also similar to the planned regimen in both arms.
Toxic death under treatment was three times higher in the cisplatin/5-FU arm as compared with S-1/cisplatin. For OS, the first primary objective of superiority was not met (HR= 0.92, Figure 3 ). However, the calculated level of OS non-inferiority was met and showed that S-1/cisplatin is non-inferior to 5-FU/cisplatin (p=0.0068). For the secondary endpoints, PFS was not superior (HR=0.99) but TTF was (HR=0.87, p=0.032) (see Figure 3) . The Forest plot in Figure 4 shows that no patient subgroups clearly benefited from either treatment regimen. There are slight advantages for both S-1 and 5-FU but no overall trend towards either treatment for any subgroup. There were similar overall response rates for S-1/cisplatin and 5-FU/cisplatin of 29.1 and 31.9 %, respectively. The Need for a New Fluoropyrimidine in Advanced Gastric Cancer Treatment The toxicity data show that higher dosages of oxaliplatin also increase grade 1 and 2 peripheral sensory neuropathy. From this trial, therefore, it can be concluded that S-1 and oxaliplatin can be administered with the biological bevacizumab and perhaps other biologics, with acceptable safety and tolerability without evidence of pharmacokinetic interactions.
In another randomised trial conducted in Asia, SOX was compared with CAPOX in the treatment of gastric cancer. 6 Both the SOX and CAPOX regimens were equally active and well tolerated in advanced gastric cancer patients. Grades 3/4 neuropathy, nausea, vomiting and asthenia were less frequent with SOX and as anticipated, HFS at any grade was more frequent for CAPOX (SOX = 3 %; CAPOX = 25 %, p=0.001). Therefore two viable treatments may reduce the risk of HFS.
One is the cisplatin/S-1 regimen in a four-weekly regimen and the other is the SOX regimen which is the 130 mg/m 2 oxaliplatin with 25 mg/m 2 S-1 BID regimen in a three-weekly cycle.
Finally, S-1 is also being developed for use in colorectal cancer and ongoing studies in Asia are comparing SOX with other combinations such as folinic acid/fluorouracil/oxaliplatin (FOLFOX).
Conclusion
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